Study guide

19.2 Hyperleukocytosis

Certified Pediatric Hematology Oncology Nurse CPHON®

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy

2 Care Continuum

2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship

3 Leukemias and Lymphomas

3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas

4 CNS, Neuroblastoma, and Renal Tumors

4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors

5 Sarcomas and Other Solid Tumors

5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors

6 Hematologic Disorders

6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure

7 Pathophysiology, Genetics, and Diagnostics

7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis

8 Clinical Trials and Professional Performance

8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education

9 Chemotherapy and Biotherapy

9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy

10 Immunotherapy, Cellular Therapy, and Radiation

10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam

11 HSCT, Surgery, Transfusion, and Coagulation Therapy

11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy

12 Neurologic, Respiratory, and Cardiovascular Effects

12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects

13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects

13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects

14 Endocrine, Hematologic, Immunologic, and Sensory Effects

14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects

15 Pain, Sleep, Fatigue, and Mental Health

15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects

16 Supportive Care

16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care

17 Infectious and Gastrointestinal Emergencies

17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction

18 Metabolic Emergencies

18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome

19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome

19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)

20 Sickle Cell and Hemostasis Emergencies

20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed

21 Cardiopulmonary Emergencies

21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias

22 Neurologic and Infusion Emergencies

22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation

23 Family, Caregivers, and Social Integration

23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment

24 Development, Grief, Culture, and Community Resources

24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources

19.2 Hyperleukocytosis

Key Takeaways Explain This Topic AI

Very high WBC, especially in monoblastic AML and T-ALL, causes leukostasis: respiratory distress, visual change, and confusion.

Hydrate; avoid routine packed red cells until the WBC is reduced because red cells raise viscosity; platelets may still be given for bleed risk.

Hydroxyurea, leukapheresis, or induction chemotherapy are team cytoreduction tools; leukapheresis does not replace disease-directed therapy.

Starting therapy raises tumor lysis syndrome risk; oxygen, ICU care, and fundoscopic exam belong with symptomatic leukostasis.

Polycythemia is high red-cell mass, not a high WBC—do not treat them as the same viscosity emergency.

Last updated: August 2026

CPHON TCO V.D.3 is hyperleukocytosis : a very high white-cell count (WBC) that can sludge in the microcirculation. This is not polycythemia, not the tumor-lysis laboratory chapter (though lysis starts when you treat), and not a demand that you memorize a single ONCC-published WBC cutoff. Many bedside pathways flag counts well above 100,000/µL, and acute myeloid leukemia (AML) —especially monoblastic disease—can produce leukostasis at lower counts than acute lymphoblastic leukemia (ALL) because myeloid blasts are large and sticky. T-cell ALL (T-ALL) is the other classic high-count picture.

A 6-year-old with monoblastic AML, a WBC of 180,000/µL, and new confusion, and a 15-year-old with T-ALL, a mediastinal mass, and a WBC of 250,000/µL are the CPHON emergencies.

Who sludges and what you see

Leukostasis is blast packing in pulmonary and cerebral capillaries. The child does not look like volume overload from a transfusion; the child looks like respiratory distress , visual change , and confusion (or headache, ataxia, or a new focal finding). Pulse oximetry may fall. The chest radiograph may show interstitial infiltrates that mimic pneumonia or pulmonary hemorrhage. Fundoscopic examination looks for retinal hemorrhages, cotton-wool spots, and papilledema—the eyes are a window on the same microcirculation that is failing in the brain. Do not skip the fundoscopic exam because the child is just anxious about the diagnosis.

Monoblastic and myelomonocytic AML (historically FAB M4/M5) also infiltrate gums and skin; gingival hypertrophy plus a sky-high WBC is a viscosity story, not a dental appointment. T-ALL adds a mediastinal mass airway risk—signpost the cardiopulmonary-emergency chapter for the mass itself, but the high count still needs this page.

Walk the 6-year-old. Newly diagnosed monoblastic AML. WBC 180,000/µL, hemoglobin 6.2 g/dL, platelets 12,000/µL. The child is tachypneic, says the lights have halos, and does not know the parent's name. This is leukostasis. Oxygen, intensive-care unit (ICU) transfer, and a fundoscopic exam happen now, while the team chooses cytoreduction. It is not a floor observation for the first night of teaching videos.

Distinguish polycythemia

Polycythemia is too much red-cell mass —high hematocrit, high hemoglobin—not too many leukocytes. Viscosity is high because erythrocytes are the main determinant of blood viscosity. Pediatric polycythemia (cyanotic heart disease, high-altitude physiology, rare myeloproliferative disease) is a different map: phlebotomy or red-cell reduction, not hydroxyurea for blasts. Do not treat a high WBC with a hematocrit protocol, and do not treat a hematocrit of 68% as hyperleukocytosis. The CPHON trap is transfusing packed red blood cells (PRBC) into a hyperleukocytosis child as if the only number that mattered were the hemoglobin.

First actions: water, oxygen, careful blood, cytoreduction

Hydration lowers viscosity by diluting the circulating blast burden and protects tubules for the tumor lysis syndrome (TLS) that starts when therapy begins. Initial fluids typically contain no potassium , as in the TLS chapter. Watch the lungs: a child with leukostasis already has a pulmonary capillary problem; dump-in volume without reassessment is how you add pulmonary edema to sludge.

Avoid routine PRBC until the WBC is reduced. Raising hematocrit raises viscosity and can worsen leukostasis and intracranial catastrophe. Anemia is real—the 6.2 g/dL still matters—but the first hours are oxygen, cytoreduction, and a team decision about a small, slow red-cell aliquot if ischemia is extreme, not a reflex two-unit catch-up. Platelets may still be given for bleed risk. Thrombocytopenia plus hyperleukocytosis is an intracranial-hemorrhage setup; platelet transfusion does not raise viscosity the way red cells do. Give platelets as ordered for a wet mouth, headache, or a critically low count.

Cytoreduction is a team choice, not a nurse-invented recipe:

Hydroxyurea to lower the count while induction is organized

Leukapheresis for selected children with symptomatic leukostasis and a usable access plan—calcium, circuit, and blood-volume issues are real in small children. Leukapheresis does not replace disease-directed therapy

Induction chemotherapy is the definitive blast-clearing move

Oxygen and ICU monitoring belong with symptomatic leukostasis. Telemetry, frequent neurologic checks, and a working airway plan sit next to the fundoscope. Do not send a confused, hypoxic newly diagnosed AML patient to a regular floor.

TLS when therapy starts

The metabolic-emergencies chapter owns the laboratory four. This page owns the reminder: the count does not vanish quietly. Hydroxyurea, leukapheresis, steroids in T-ALL, and induction all dump potassium, phosphate, and uric acid. Start TLS precautions with cytoreduction—hydration without potassium, allopurinol or rasburicase per protocol, telemetry—not after the first arrhythmia. A 15-year-old with T-ALL whose WBC is crashing after the first steroid doses is a TLS patient even if leukostasis is improving.

Teach families why the red-cell bag is being held, why platelets may still go in, why the eye doctor is in the room, and why the child is in the ICU: the white cells are crowding the smallest blood vessels in the lungs, brain, and retina. That sentence is more useful than the word hyperleukocytosis alone.

  • Feature Hyperleukocytosis / leukostasis Polycythemia
  • Cell that raises viscosity Blasts (WBC very high) Red cells (hematocrit high)
  • Classic pediatric oncology Monoblastic AML, T-ALL Not the usual new-leukemia script
  • Bedside signs Respiratory distress, visual change, confusion Plethora, headache; not blast sludge
  • Red cells Avoid routine PRBC until WBC falls Problem is already too many red cells
  • Platelets May give for bleed / CNS risk Not the viscosity lever
  • First cluster Oxygen, ICU, hydration, cytoreduction, fundoscopic exam Do not treat as a blast emergency

That is TCO V.D.3: name monoblastic AML and T-ALL, treat respiratory-visual-confusion clusters as leukostasis, hydrate, hold routine PRBC, give platelets when bleeding is the risk, start hydroxyurea or leukapheresis or induction as the team orders, watch TLS, and look in the eyes.

Loading diagram... Hyperleukocytosis: leukostasis actions versus polycythemia

Leukostasis teaching emphasis by picture (relative, not incidence)